Literature DB >> 10433722

Heterogeneity in the actions of drugs that bind in the DNA minor groove.

F G Albert1, T T Eckdahl, D J Fitzgerald, J N Anderson.   

Abstract

Distamycin and Hoechst 33258 have long served as the model compounds for biochemical, biophysical, and clinical studies of the drugs that bind in the DNA minor groove. However, the results presented in this investigation clearly show that 4,6-diamidino-2 phenylindole (DAPI) is superior to both of these drugs at negating the effects of intrinsic DNA curvature and anisotropic bendability as measured by electrophoretic and ligation analysis. In addition, DAPI was more effective than distamycin and Hoechst 33258 at inhibiting the assembly of nucleosomes onto synthetic and natural sequences that have multiple closely spaced oligo-AT sequences that serve as drug binding sites. Since these effects may be related to the biological action of the drugs, it was of interest to determine the mechanism that was responsible for the enhanced action of DAPI. The possibility that the differential drug potencies resulted from differential overall affinities of the ligands for A-tract molecules was considered, but drug binding studies suggested that this was not the case. It is also unlikely that the differential drug effects resulted from the binding of the drugs to different DNA sites since the oligo A/T binding sites for DAPI and Hoechst were centered on the same nucleotide positions as revealed by footprinting studies using exonuclease III, DNase I, and hydroxyl radical. However, the footprinting studies with DNase I did uncover a potentially important difference between the drugs. DAPI protected only the AT bp in the binding sites, while distamycin and Hoechst protected these bp as well as flanking Gs and Cs. These results permitted us to advance a preliminary model for the enhanced action DAPI. According to the model, the short length of DAPI and its absolute specificity for A/T bps with narrow minor grooves ensures that only particularly minor grooves that give rise to curvature and anisotropic bendability are occupied by the drug. Consequently, each helical deflection induced by an A-tract in the absence of the drug is countered by an opposite deflection induced by DAPI binding, thus effectively neutralizing intrinsic curvature and bending into the minor groove.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433722     DOI: 10.1021/bi990382p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Mapping noncovalent ligand binding to stemloop domains of the HIV-1 packaging signal by tandem mass spectrometry.

Authors:  Kevin B Turner; Nathan A Hagan; Andrew S Kohlway; Daniele Fabris
Journal:  J Am Soc Mass Spectrom       Date:  2006-07-26       Impact factor: 3.109

2.  Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides.

Authors:  Thomas D Schaal; William G Mallet; Dustin L McMinn; Nam V Nguyen; Michelle M Sopko; Sam John; Bhavin S Parekh
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.

Authors:  D W Jun; Y S Jeong; H J Kim; K-C Jeong; S Kim; C-H Lee
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Determination of DNA content of aquatic bacteria by flow cytometry.

Authors:  D K Button; B R Robertson
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

5.  No Structure-Switching Required: A Generalizable Exonuclease-Mediated Aptamer-Based Assay for Small-Molecule Detection.

Authors:  Juan Canoura; Zongwen Wang; Haixiang Yu; Obtin Alkhamis; Fengfu Fu; Yi Xiao
Journal:  J Am Chem Soc       Date:  2018-07-26       Impact factor: 15.419

6.  Utilization of Guanidine-Based Ancillary Ligands in Arene-Ruthenium Complexes for Selective Cytotoxicity.

Authors:  Jit Karmakar; Promita Nandy; Saurabh Das; Debalina Bhattacharya; Parimal Karmakar; Samaresh Bhattacharya
Journal:  ACS Omega       Date:  2021-03-19

7.  Rapid determination of the active fraction of DNA repair glycosylases: a novel fluorescence assay for trapped intermediates.

Authors:  Jeffrey O Blaisdell; Susan S Wallace
Journal:  Nucleic Acids Res       Date:  2007-02-08       Impact factor: 16.971

8.  Microarray analysis of the in vivo sequence preferences of a minor groove binding drug.

Authors:  Todd T Eckdahl; Adam D Brown; Steven N Hart; Kelly J Malloy; Martha Shott; Gloria Yiu; Laura L Mays Hoopes; Laurie J Heyer
Journal:  BMC Genomics       Date:  2008-01-23       Impact factor: 3.969

9.  Introducing structure-switching functionality into small-molecule-binding aptamers via nuclease-directed truncation.

Authors:  Zongwen Wang; Haixiang Yu; Juan Canoura; Yingzhu Liu; Obtin Alkhamis; Fengfu Fu; Yi Xiao
Journal:  Nucleic Acids Res       Date:  2018-07-27       Impact factor: 16.971

10.  HIV chromatin is a preferred target for drugs that bind in the DNA minor groove.

Authors:  Clayton K Collings; Donald W Little; Samuel J Schafer; John N Anderson
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.